Faricimab
Faricimab is a humanized bispecific antibody injection medication used to treat certain retinal eye conditions. It works by simultaneously inhibiting two pathways (VEGF-A and Ang-2) that contribute to abnormal blood vessel growth and fluid leakage in the retina. This medication is used in adults with neovascular (wet) age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion.
Faricimab is an eye injection that treats retinal conditions by blocking two pathways involved in abnormal blood vessel growth and fluid leakage.
Key facts at a glance
- ATC
- S01LA09
- RxNorm
- 2591519
- Generic
- Faricimab
- Class
- atc-s01
- Brands
- Vabysmo
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection, prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 6mg (0.05mL of 120mg/mL solution)
- Maximum
- consult physician
- Frequency
- every 4 weeks for first 4 doses, then every 8-16 weeks based on response
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- not approved for pediatric use
- Maximum
- consult physician
- Frequency
- not applicable
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 6mg (0.05mL of 120mg/mL solution)
- Maximum
- consult physician
- Frequency
- every 4 weeks for first 4 doses, then every 8-16 weeks based on response
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
8 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks to the mother
regular fetal monitoring recommended
Use with caution and monitor for adverse effects.
pregnancy
second trimesteravoid if possible
use only if clearly needed, discuss risks and benefits with patient
regular prenatal check-ups
Use with caution and monitor for adverse effects.
pregnancy
third trimesteravoid if possible
consider delaying treatment until after delivery if clinically appropriate
regular fetal monitoring
Use with caution and monitor for adverse effects.
lactation
breastfeedingno specific adjustment
discontinue breastfeeding or interrupt treatment, decision should be based on importance of drug to mother
monitor infant for potential effects
Use with caution and monitor for adverse effects.
geriatric
elderlyno dosage adjustment required
safe for use in elderly patients, commonly used for age-related macular degeneration
routine ophthalmologic monitoring
pediatric_age
children 0 18not established
use only if benefits outweigh potential risks, limited clinical trial data in pediatric populations
close ophthalmologic monitoring
renal_impairment
mild to moderateno dosage adjustment needed
no specific adjustments required due to intravitreal administration and minimal systemic absorption
standard monitoring
hepatic_impairment
mild to moderateno dosage adjustment needed
no specific adjustments required due to minimal systemic exposure
standard monitoring
Statistics and clinical data
FDA approval year
Initial FDA approval date for Faricimab (Vabysmo)
Drug class
Pharmacological classification of Faricimab
Primary indications
Therapeutic indications for Faricimab
Route of administration
Method of drug administration
Faricimab is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). It is administered as an intravitreal injection by an eye care professional.
Faricimab is a bispecific antibody that binds to and inhibits both VEGF-A and Ang-2. By blocking VEGF-A, it reduces endothelial cell proliferation, abnormal blood vessel growth (neovascularization), and vascular leakage. By inhibiting Ang-2, it promotes vascular stability and reduces inflammation, providing a dual mechanism for treating retinal vascular diseases.
Faricimab is administered by injection into the eye (intravitreal injection) by a qualified healthcare professional in a clinical setting. Common side effects may include conjunctival hemorrhage, eye discomfort, and increased intraocular pressure. Patients should report any signs of infection (pain, redness, sensitivity to light, vision changes) immediately. Treatment intervals may be adjusted based on individual response, with some patients potentially extending intervals up to every 16 weeks after initial dosing.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy